The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| DRTS | +68.82% | N/A | N/A | -63% |
| S&P | +13.19% | +87.83% | +13.42% | +76% |
Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company. It focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.
The stock enjoyed another big gain.
The company is developing a promising type of radiation treatment for solid tumors.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | $0.00M | 0.0% |
| Market Cap | $264.26M | 49.7% |
| Market Cap / Employee | $2.36M | 0.0% |
| Employees | 112 | -7.4% |
| Net Income | -$10.11M | -37.3% |
| EBITDA | -$9.31M | -10.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $15.26M | 159.6% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $12.23M | 6.2% |
| Short Term Debt | $1.08M | 4.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -34.01% | -7.4% |
| Return On Invested Capital | -53.05% | 2.6% |
No data available for this period.
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.25 | 3.13 | 2.82 | 3.91 | 74.88% |
| Price to Tangible Book Value | 2.25 | 3.13 | 2.82 | 3.91 | 74.88% |
| Enterprise Value to EBITDA | -18.83 | -15.94 | -19.42 | - | |
| Return on Equity | -37.2% | -43.2% | -48.0% | -43.8% | 32.14% |
| Total Debt | $12.57M | $12.54M | $12.29M | $13.31M | 6.02% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
